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ABSTRACT
Iron catalyzes cytosolic reactions that promote cancer cell proliferation. The latter is
responsible for the poor survival rate of cancer patients. One approach to reduce iron enhanced
tumor growth is through the use of iron chelators that are site-directed to the tumor site. This
paper reports a simple method for designing gold nanoparticles (AuNPs) as a molecular vehicles
to transport folic acid targeting moieties and 5-amino-8-hydroxyquinoline (AHQ) iron chelators
to cancer cells. The AHQ chelators and folic acid targeting moieties were coupled to glutathione
synthon for surface conjugation to AuNPs. Thin layer chromatography (TLC), and infrared (IR),
and 1H-NMR spectroscopies determined the surface-modified AuNPs were pure with no excess
ligands and provide evidence for conjugation of the chelator and targeting moiety to the AuNPs
surface. Fluorescence spectroscopy also confirmed the presence of the ligands on the AuNP
surface. The capacity of the gold nanochelators to bind to metals was assessed by UV-Vis and
dynamic light scattering (DLS) spectroscopies upon incubation with different types of metal ion
and at different concentrations. We can preliminary rank the metal binding affinities to the
nanochelators in order of decreasing affinity as follows: Cu(II) > Zn(II) > Fe(III) > Ca(II) > K(I)
> Na(I) at pH 6.5 and K(I) > Cu(II) > Na(I) > Zn(II) > Ca(II) > Fe(III) at pH 8.0. The synthetic
route employed allows for the development of a library of tailored and targeted chelator ligands
using biocompatible AuNPs with high potential towards controlling iron concentrations in cancer
cells.
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CHAPTER 1

INTRODUCTION

Cancer is the second deadliest disease in America following heart disease.1 In 2015,
approximately 600,000 Americans are expected to die of cancer and 1.7 million new cancer
cases to be discovered in 2015.2 Furthermore, while 33.5% of new cancer patients in 2005-2011
have died 5 years after being diagnosed with cancer, some 39.6% of the population are estimated
to have cancer at some point of their life.2 In 2013, the total national health expenditures for
cancer treatment and diagnosis amounted to $2.9 trillion, corresponding to 17.4% of the Gross
Domestic Product.3 Hence, early diagnosis and treatment are very crucial to increase cancer
survival and reduce direct medical costs.
Understanding the process of tumor development is the initial step towards improving
cancer diagnosis and treatment. With respect to the mechanism of cancer cell proliferation, iron
is a known factor in tumor growth due to its catalytic effect on cell division and the production of
reactive oxygen species (ROS).4 More specifically, certain types of cancer, such as breast and
thyroid cancers, are demonstrated to overexpress iron import protein (transferrin) and suppress
iron export protein (ferroportin) on the cell surface (Scheme 1),4,5 leading to a substantial
increase in iron uptake. For instance, in breast cancer, the amount of iron increases from 299 to
376 µg per gram of tissue while that in thyroid cancer from 569 to 1397 µg.6 As a result, the
activity of ribonucleotide reductase (RNR), an iron-dependent enzyme responsible for the
synthesis of DNA, is highly catalyzed promoting cell over-multiplication.7 In this process,
Fe(III) is reduced by RNR to Fe(II) in presence of peroxide in Fenton-type reactions to produce
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ROS.8,9 These ROS, lead to cell death by inducing oxidative stress upon bi
binding
nding to DNA with
high affinity and promote carcinogenesis by stimulating c-Myc oncogene.10

Scheme 1. Iron metabolism in cancer.

cells, a wide spectrum of iron-chelating
chelating ligands have
Since iron plays a role in cancer cells
been designed and studied in clinical trials for their antip
antiproliferative
roliferative and antitumor activities.
Typical examples of these ligands include desferrioxamine,11 pyridoxal isonicotinoyl
hydrazine,12 thiosemicarbazones,13,14 and tachpyridine (Table 1).15,16 These chelators have
h
been
shown to bind efficiently
fficiently to iron, inhibit RNR activity in DNA synthesis, and reduce tumor
metastasis.13,14 Nonetheless, their cancer act
activity is highly limited by their low permeability
through cell membranes, affinity to other essential trace elements in the cell such as Ca(II) and
Mg(II), and more importantly lack of specificity to tumors.
One approach to tackling the issue of lack of sspecification to cancer cells is through the
use of targeting strategy where the therapeutic recognizes only cancer cells.
cells Due to the
overexpression of folate receptor α (FRα)) in certain types of cancer, such as breast and ovarian
9
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cancers,17,18 folic acid (FA), a ligand with high affinity to FR
FRα,, has been employed as an efficient
cancer targeting moiety and drug delivery age
agent.19,20 Even though
ugh the cause for FRα
FR
overexpression remains unclear, FA has been studied widely in vitro for the delivery of
radiopharmaceuticals, liposomal drug carriers, gene transfer vectors, and protein toxins.19
Moreover, examples of folate-based
based chemotherapeutic and imaging agents developed for clinical
studies include folate-tubulysin,
tubulysin,21 etarfolatide,22,23 and vintafolide.24 Recently, FA was also
conjugated on a variety of nanoparticles (NPs) for the use in cancer nanomedicine. Their
application cancer nanotechnology spreads over a wide spectrum of target
targeted
ed drug carriers,
contrasting agents, thermal therapy agents, radio
radiosensitizers,, and photosensitizers.25,26

Table 1. Natural and synthetic chelators for cancer therapy.
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Existing nanoparticles that are currently being explored for cancer therapy include
polyethylene glycol (PEG)-coated NPs,27 chitosan-coated NPs,28 silver NPs,29 iron oxide NPs,30
carbon nanotubes,31 and quantum dots.26 In addition, gold nanoparticles (AuNPs) have also
emerged as promising novel agents for drug delivery, optical agents, and photothermal agents
with other unique electronic and optical properties.25 In addition, they have high biocompatibility,
easy surface modification, high permeability through blood brain barrier, and large surface areato-volume ratio.25 Especially, the latter enables the AuNPs to be coated with a large number of
surface ligands, leading to the heavy dependence of many of their physicochemical properties on
the nature of the molecules packed on the NP surface. In the absence of the targeting moiety,
AuNPs usually passively accumulate into cancer cells through phagocytosis and pinocytosis.32,33
Functionalization of the nanoparticle surface with ligands, such as FA, that target specific
receptors on cell surface has been proven to enhance AuNP internalization through receptormediated endocytosis.34,35
The use of AuNPs as potential carriers of metal chelators for iron depletion in cancer
nanotechnology still remains under development. Recently, monolayer-capped AuNPs were
employed as colorimetric sensors for the detection of an array of heavy metal ions such as Ag(I),
Hg(II), Cd(II), Fe(III), Pb(II), Al(III), Cu(II), Zn(II), and Cr(III).36–39 Additonally, polysorbate80 coated polybutylcyanoacrylates nanoparticles using the iron chelator 2-methyl-N-(2′aminoethyl)-3-hydroxyl-4-pyridinone in Alzheimer therapy has recently become research topic
of interest.40 Herein, we report the design of water-soluble gold nanoparticles as nanocarriers of
the FA targeting moiety and iron chelator 5-amino-8-hydroxyquinoline (AHQ). AHQ is a
derivative of 8-hydroxyquinoline, a chelator with a high affinity to metals and a strong candidate
for antitumor activity,41,42 which allows for derivatization of its amine at the 5-position of the
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quinoline. The AHQ chelators and the FA targeting moieties were coupled onto the glutathione
glutath
synthons before conjugation to the gold cores ((Scheme 2).
). Ultracentrifugation is used as the
method of purification to remove free ligands and impurities to increase the stability, solubility,
and biocompatibility of the NP system. The chelating capacity of the nanochelators was also
evaluated towards a variety of essential trace cell
cellular
ular metals such as Cu(II), Fe(III), Zn(II),
Ca(II), Na(I), and K(I). More importantly, this work provides a facile route for the development
of a novel class of targeted chelators using biocompatible AuNPs as a platform with high
potential toward future biomedical
iomedical applications such as X-ray
ray scattering imaging and thermal

Scheme 2. Design of gold nanochelator for cancer therapy.

therapy agents.
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CHAPTER 2

EXPERIMENTAL SECTION

Materials and general information
HAuCl4●H2O is purchased from Strem Chemicals, Inc. Sodium citrate (Na3C6H5O7),
folic acid, L-glutathione reduced (GSH), 5-amino-8-hydroxyquinoline dihydrochloride, and
N,N′-diisopropylcarbodiimide

are

purchased

from

Sigma-Aldrich

Chemical

Co.

N-

hydroxysuccinimide (NHS) is purchased from Acros. All chemicals are used as received.
Nanopure water is obtained from a Milli-Q ultra-pure system. A Thermo Scientific Sorvall ST
40R at 4700 rpm and Sartorius Stedim Biotech ultracentrifugation concentrators with a PES
membrane (Vivaspin 20, MWCO = 10 K) is employed for purification while the purity is
assessed using thin layer chromatography with 5x20 cm silica gel 1B plates, a mixture of
butanol/acetic acid/water (12:3:5) as the mobile phase and ninhydrin. Physical measurements

Fluorescence, UV-Vis, and Dynamic Light Scattering Measurements.
Fluorescence is recorded on a PTI spectrophotometer using Felix32 software at excitation
wavelengths of 270 and 350 nm. A USB4000 UV−visible-NIR spectrophotometer (Ocean Optics,
Dunedin, FL, USA) is used to record UV-Vis spectra. Both fluorescence and UV-Vis
measurements are taken in a 1.0 cm path length quartz cell. Dynamic light scattering (DLS)
measurements are performed with an LB-550 particle size analyzer (Horiba Co. Ltd., Fukushima,
Japan) and 1H-NMR with a Bruker Advance II 400 mHz instrument (The Woodlands, TX, USA).
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Synthesis of citrate-stabilized AuNPs (Au-Cit)
Citrate-stabilized AuNPs are prepared according to G. Frens.43 HAuCl4 x H2O (0.0183 g,
0.0539 mmol) is dissolved in 10 mL of H2O to create a pale yellow solution. Sodium citrate
(0.0449 g, 0.1506 mmol) is dissolved in 5 mL of H2O. 85 mL of H2O is heated on a hotplate until
a rolling boil is observed. Then, HAuCl4 solution is added into the boiling water, followed by the
sodium citrate solution. At this point, the final solution turned dark grey then dark purple and
eventually purplish red. It is stored at 10oC. The UV-Vis in H2O had a λmax at 522 nm.

Synthesis of folate-conjugate glutathione (GSH-FA)
Folic acid (0.1000 g, 0.23 mmol) is dissolved in 2 mL of 1 M NaOH. To this yellow
solution is added DIC (70.16 µL, 0.23 mmol) followed by NHS (0.1043 g, 0.23 mmol). The
resulting FA-NHS solution is stirred vigorously for 30 min before being rotary evaporated. The
solid is then washed with 20 mL dichloromethane (DCM) 5 times. After the last wash, the solid
is air-dried to remove remaining DCM. The concentration of FA-NHS in 2 mL H2O is calculated
to be 113.28 mM. GSH (0.0500 g) is dissolved into 2 mL of H2O followed by the addition of
1.44 mL of 113.28 mM FA-NHS and stirring for 3 h. The final concentration of GSH-FA in 2
mL of H2O is calculated to be 81.35 mM. The purity of the material is assessed by TLC with a
mixture of butanol/acetic acid/water (12:3:5) as the mobile phase and a ninhydrin solution (9.9
mM) as detection agent for amines (Rf of impurities = 0.14 and 0.37). UV-Vis in H2O has λmax at
270 and 360 nm. Fluorescence in H2O has λem at 450 nm when λex = 350 nm.

1

H NMR (400

MHz, D2O) d ppm 2.87 (dd, J=14.31, 9.79 Hz, 1 H) 3.22 (dd, J=14.31, 4.27 Hz, 1 H) 3.53 (t,
J=6.40 Hz, 1 H) 3.68 (d, J=5.02 Hz, 2 H) 4.21 (dd, J=8.78, 4.77 Hz, 1 H) 4.41 (s, 2 H) 6.65 (m,
J=9.03 Hz, 2 H) 7.55 (m, J=8.78 Hz, 2 H) 8.47 (s, 1 H).
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Synthesis of 5-amino-8-hydroxyquinoline and folate-conjugate glutathione (GSHFA-(AHQ)2)
Into 1 mL of 81.35 mM GSH-FA in H2O is added DIC (50.39 µL, 0.33 mmol), NHS
(0.0749 g, 0.65 mmol), and AHQ (0.0758 in 2 mL of MeOH, 0.33 mmol). AHQ is purchased as
a dihydrochloride salt, and is neutralized in MeOH with 2 eq NaOH before addition to GSH-FA.
The resulting solution is stirred vigorously for 3 hours before rotary evaporation. After removing
all solvents, the brown solid is redispersed in 5 mL H2O and washed with DCM extensively until
the wash is completely colorless. Afterwards, the solution is rotary evaporated again to remove
DCM traces, and redispersed in 2 mL of H2O. The final concentration of GSH-FA-(AHQ)2 in 2
mL of H2O is calculated to be 81.35 mM. The purity of the material is assessed by TLC with a
mixture of butanol/acetic acid/water (12:3:5) as the mobile phase and a ninhydrin solution (9.9
mM) as detection agent for amines (Rf of GSH-FA-(AHQ)2 = 0.2034). UV-Vis in H2O has λmax
at 260 and 360 nm. Fluorescence in H2O had λem at 450 nm when λex = 350 nm. 1H NMR (400
MHz, D2O) d ppm 3.09 (t, J=6.65 Hz, 16 H) 3.69 (d, J=4.52 Hz, 30 H) 4.21 (ddd, J=8.85, 4.58,
2.13 Hz, 8 H) 4.40 (br. s., 6 H) 6.58 (d, J=8.78 Hz, 9 H) 6.77 (d, J=8.53 Hz, 7 H) 7.50 - 7.59 (m,
20 H) 8.57 (s, 4 H).

Preparation of Au-GSH-FA
Into 100 mL of Au-Cit (Optical density (O.D.) = 0.107 for 100 uL of stock diluted to 1
mL with H2O, 20 nm diameter) is added 25 mL of 0.33 mM GSH-FA. The solution is stirred for
24 hours, followed by ultracentrifugation with a Vivaspin 20 concentrator at 4700 rpm with 10
mM phosphate buffer at pH 8.0 to remove excess ligands. The purity of the material is assessed
with TLC with a butanol/acetic acid/water mixture (12:3:5) as mobile phase and a ninhydrin
solution (9.9 mM) as detection agent for amines. The UV-Vis in H2O has a λmax at 525 nm.
15
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Preparation of GSH-FA-(AHQ)2
Into 100 mL of Au-Cit (O.D. = 0.107 for 100 uL of stock diluted to 1 mL with H2O, 20
nm diameter) is added 25 mL of 0.33 mM GSH-FA-(AHQ)2. The solution is stirred for 24 hours,
followed by ultracentrifugation with a Vivaspin 20 concentrator at 4700 rpm with 10 mM
phosphate buffer at pH 8.0 to remove excess ligands. The purity of the material is assessed with
TLC with a butanol/acetic acid/water mixture (12:3:5). The UV-Vis in H2O has a λmax at 530 nm.

Cyanide etching studies of Au-GSH-FA and Au-GSH-FA-(AHQ)2
Purified samples of Au-GSH-FA (800 µL of O.D. = 0.391) and Au-GSH-FA-(AHQ)2
(684 µL of O.D. = 0.385) are incubated with KCN (10 µL, 307 mM) until the solutions turn
colorless. The etched samples are diluted to a 1 mL with H2O to obtain a final [KCN] of 3.07
mM.

Metal Affinity Study of Au-GSH-FA and Au-GSH-FA-(AHQ)2
Two solutions of 48 mL of Au-GSH-FA (O.D. = 0.391) and 41.04 mL of Au-GSH-FA(AHQ)2 (O.D. = 0.385) are buffered with each of 1 M PB pH 8.0 and 1M HEPES pH 6.5, and
diluted to 50 mL with H2O to obtain the final [PB] and [HEPES] of 10 mM. Three 1000 µL trials
of each type of AuNP in each buffer are incubated with 0 to 10 µL of each 33 mM Cu(II), Fe(III),
and Zn(II) followed by dilution to 1010 µL with H2O. The final concentrations of metal in these
samples are 0, 33, 65, 98, 131, 163, 196, 229, 261, 294, and 327 µM.
Three other 1000 µL trials of each type of AuNP in each buffer is incubated with 1 µL of
each 33 mM Ca(II), Na(I), and K(I) followed by dilution to 1010 µL with H2O. The final
concentrations of metal in these samples are 33 µM. All the samples are recorded for UV-Vis,
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but only those incubated with 1 µL of 33 mM Cu(II), Fe(III), and Zn(II) are recorded for
hydrodynamic diameter (HD) using DLS.
CHAPTER 3

SYNTHESIS OF GSH-FA AND GSH-FA-(AHQ)2 LIGAND SCAFFOLDS

The first stage in the preparation of gold nanochelators is the synthesis of the ligand
scaffold with the targeting ligands. Using glutathione as a synthon, one of the carboxylate
residues of FA is coupled with the amine of the tripeptide (Scheme 3). This reaction produces a
mixture of γ- and α-substituted regioisomers with a ratio of 4:1 as the separation of the two
species is difficult.44,45 Literature precedents show that modification at the either position does
not affect the ability of FA to recognize human FRα receptor since the preferred binding site on
the FA molecule is its pterin headgroup.19,45–47
We prepared the GSH-FA using DIC/NHS coupling chemistry (Scheme 3).48 Since FA is
slightly soluble in water (0.01 mg/mL at 0°C),49 1 M NaOH is used to deprotonate the carboxylic
acids to yield a transparent yellow solution (50 mg/mL 1 M NaOH).49 DIC and NHS are used as
coupling agents in a 1:2 ratio to FA to produce N-hydroxysuccinimide active folate conjugate
(FA-NHS). The N-hydroxysuccinimide derivative of FA increases the stability of the activated
carboxylate residue of FA in water.48 Self-coupling of FA between its carboxylate and amine
residues is not expected since the lone pair of the amine is delocalized on the pteroate group.
White precipitates of N,N'-diisopropylurea byproduct are removed by DCM extraction to obtain
purified GSH-FA. To confirm the purity and to access the coupling efficiency of the product we
employed thin layer chromatography (TLC) and 1H-NMR spectroscopies are performed (vide
infra).
17
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Scheme 3. Synthesis of GSH
GSH-FA.

TLC of GSH-FA is performed on a Silica 1B plate using a mixture of butanol/acetic
acid/water (12:3:5) followed by spraying with ninhydrin for visualization ((Figure
Figure 1). Rf values
for the spots upon ninhydrin staining are calculated and tabulated in Table 2. Figure 1 shows the
TLC plates of GSH, FA, FA-NHS
NHS and GSH
GSH-FA
FA under natural light with ninhydrin
ninhy
(Figure 1A
(a-d)) and UV light (Figure 1B
B ( a-d)).
d)). Purple spots appear on the lanes spotted with GSH,
DIC/NHS, and GSH-FA
FA with Rf values of 0.2542, 0.2712, and 0.0334, respectively. No excess
DIC and NHS remain after DCM extraction as evidenced by lack of spots for byproducts
byproduct of
DIC/NHS and FA-NHS lanes (Figure
Figure 1A c-d).
d). However, traces of oxidized GSH are seen on the
GSH-FA column (Figure 1A (e)). This suggests that the coupling of the γ-carboxylic
carboxylic group of
FA to the amine of GSH is not 100% coupling given that reduced GSH is known to be easily
oxidized in basic environment.
18
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A)

B)

a b c c e f

g h i

a b c c e f

g h i

Figure 1. Pictures of TLC plates of ((a) GSH, (b) FA, (c) FA-NHS, (d)) DIC/NHS, (e)
(
GSH-FA, (f) AHQ ● 2HCl, ((g) AHQ ● 2HCl + 2 eq NaOH, (h) AHQ●
●2HCl + 4 eq
NaOH, and (i) GSH-FA-(AHQ)
(AHQ)2 under different testing conditions: (A)) upon spraying
with ninhydrin and under regular light, and ((B)) upon spraying with ninhydrin and under
UV-lamp.

Table 2. Rf values of the final products, reagents, impurities used for the syntheses of
GSH-FA and GSH-FA-(AHQ)
(AHQ)2.

To confirm the purity and coupling efficiency of GSH
GSH-FA, 1H NMR spectroscopy is
employed and a representative 1H NMR spectra of GSH-FA and its precursors are shown in
Figure 2. The –CH
CH proton of GSH ((Figure 2A (f)) adjacent to conjugated amine normally
19
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appears as a triplet at 3.74 ppm, but shifts upfield to 3.53 ppm in GSH-FA (Figure 2C (f)). Even
though difficult to assign due to overlapping with protons of GSH and any possible impurities in
the region 1.5-3.0 ppm, the –CH2 protons (Figure 2B (g, h)) of FA adjacent to the conjugated
carboxylate appear to shift upfield to 2.4 and 2.0 (Figure 2C (g-h)), respectively upon
conjugation. Even though not adjacent to the coupling site, the protons of the pteroate residue
(Figure 2 (j, k, l, and m)) and of the glutamate residue (Figure 2 (i)) of FA shift downfield from
6.50, 7.42, 4.25, and 8.30 to 6.65, 7.55, 4.41, and 8.47 ppm, respectively. These proton
signatures are characteristic features of successful folate conjugate synthesis reported in the
literature.50 Together with TLC, 1H NMR determines that the synthesis GSH-FA has very
minimal impurities.

A)

B)

C)

Figure 2. 1H NMR spectra of (A) GSH, (B) FA, and (C) GSH-FA in D2O.
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GSH
scaffold.
The second stage is the addition of the AHQ chelator ligands to the GSH-FA
The two the GSH carboxylate residues on GSH
GSH-FA
FA are coupled with the amine of AHQ in a 1:1
ratio (Scheme 4)) using similar DIC/NHS coupling chemistry employed in the first stage. Since
AHQ is purchased as dihydrochloride salt, neutralization of the acid is necessary to enhance the

Scheme 4. Synthesis of GSH
GSH-FA-(AHQ)2.

nucleophilicity of the AHQ amine. Since the neutralization process also decreases
decrease the solubility
of AHQ in H2O, MeOH is employed to solubilize AHQ. After the synthesis, DCM is also
employed to remove excess AHQ, DIC, and NHS, given that neutralized AHQ is also soluble in
DCM. Finally, to keep the ligand soluble in water, 1 M NaOH is used to deprotonate the
hydroxyl of AHQ residues of the thiolate product GSH
GSH-FA-(AHQ)2.

(AHQ)2 is performed on a Silica 1B plate using a mixture of
TLC of GSH-FA-(AHQ)
butanol/acetic acid/water (12:3:5) followed by spraying with ninhydrin for visualization (Figure
(
1). Rf values for the spots are calculated and tabulated in Table 2). Lanes f-h
h depict different
charged species of AHQ upon the addition of different equivalents of NaOH (Figure
Figure 1 (f-h)). No
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similar spots are observed on the lane of GSH-FA-(AHQ)2 in the presence of ninhydrin (Figure
1A (i)), suggesting no excess AHQ remaining after DCM extraction. The spot for GSH-FA(AHQ)2 could be observed under UV-lamp at Rf = 0.2034 (Figure 1B (i)).
1

H NMR spectra of GSH-FA-(AHQ)2 and its building blocks are taken to confirm the

conjugation of AHQ onto the GSH residues (Figure 3). The –CH proton of GSH-FA (Figure 3A
(f)) adjacent to conjugated carboxylate residues normally appears as a triplet at 3.53 ppm, but
shifted upfield to 3.09 in GSH-FA-(AHQ)2 (Figure 3C (f)). Even though not adjacent to the
coupling site, the protons of the pteroate residue of GSH-FA shifted downfield from 7.58 and
6.77 ppm (Figure 3C (j, k)). The –CH proton next to the α-carboxylate of the glutamate residue
of GSH-FA is split into a ddd from a dd (Figure 3C (i)). The protons of AHQ (Figure 3C (r, q, o,
and p)) shift upfield from 7.38, 8.03, and 9.02 to 6.59, 7.35, and 7.91 ppm, suggesting coupling
of the AHQ ligand on the GSH-FA framework.
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Figure 3. 1H NMR spectra of (A) GSH-FA, (B) AHQ●2HCl, and (C) GSHFA-(AHQ)2 in D2O.
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CHAPTER 4

SYNTHESIS OF THIOLATED-CAPPED GOLD NANOPARTICLES

Conjugation of GSH-FA and GSH-FA-(AHQ)2 on AuNPs
Each thiolated ligand is theoretically associated with one binding site on the AuNP
sphere. To determine the stoichiometric amount of each type of ligand needed, it is necessary to
calculate the number of binding sites per nanoparticle. The optical density (O.D.) of the stock
solution of Au NP is obtained via UV-Vis spectroscopy and converted to concentration using
Beer-Lambert Law following the equation

ln ε = k ln D + A (1),
where k and A are 3.32 and 10.8 respectively.51 The value D in the equation is diameter of the
AuNP sphere is determined by TEM image.43 In this study, citrate-capped Au NPs are estimated
to have an average diameter of 20 nm. The number of entities (N) per mL is determined using
Avogadro’s number, N A , and the concentration C of the nanoparticles in the following equation

N = NAC (2).
An AuNP sphere with a diameter of 20 nm has an estimated number of 7.79x103 gold
atoms on the surface and a surface area of 1.28x103 nm2. Due to the larger structure of GSH-FA
and GSH-FA-(AHQ)2, which have projection areas of 1.74 and 2.43 nm2, we do not expect at
1:1 covalent attachment of the thiolate ligands to the Au0 atoms.52,53 Therefore, based on the
estimated projection areas of ligands, we estimate 725 molecules of GSH-FA and 519 molecules
of GSH-FA-(AHQ)2 will be covalently attached to the AuNPs surface. Therefore, for 1 mL
solution of 0.8 O.D. theoretically 5.67 nmol of GSH-FA and 4.06 nmol of GSH-FA-AHQ.
24

Tan Pham-Duy Nguyen

©Mackiewicz Research Group

However, to maximize the conjugation of the thiolated ligands onto AuNPs surface, a 10fold excess of each ligand is incubated with Au-Cit nanoparticles overnight to produce two
thiolated ligand-capped AuNPs denoted Au-GSH-FA and Au-GSH-FA-(AHQ)2 (Error!
Reference source not found.Error! Reference source not found.). The AuNPs are purified
extensively using ultracentrifugation and PB at pH 8.0. Afterwards, they are diluted with H2O
and buffered to 10 mM PB at pH 8.0 or 10 mM HEPES at pH 6.5 for further characterization.
The purity of the AuNPs is accessed using TLC, UV-Vis, and fluorescence spectroscopies.
Scheme 5. Synthesis Au-GSH-FA and Au-GSH-FA-(AHQ)2.

Au-Cit

GSH-FA-(AHQ)2

GSH-FA

The UV-Vis spectra of Au-GSH-FA and Au-GSH-FA-(AHQ)2 show characteristic
localized surface plasmon resonance (LSPR) band at λmax of 521 and 525 nm in 10 mM PB pH
8.0 (Figure 4A (a, c)). The absorption band of Au-GSH-FA does not shift when switched to 10
mM HEPES pH 6.5, suggesting no close interactions happening between the AuNPs.
Nevertheless, in presence of AHQ, the LSPR of Au-GSH-FA-(AHQ)2 red-shifts to 537 nm in 10
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mM PB HEPES pH 6.5 (Figure 4A (d)), suggesting close interactions of the AuNPs. These close
interactions of the Au-GSH-FA-(AHQ)2 could be a result of π-π stacking of the AHQ molecules
on the AuNP surface at pH 6.5. The changes in the SPR is similar to AuNPs reported where there
is an increase in FWHM (full width half max) such as the thione-capped AuNPs.54 Despite the
minimal difference in LSPR between Au-GSH-FA and Au-GSH-FA-(AHQ)2 in 10 mM PB pH
8.0, the greater FWHM Au-GSH-FA-(AHQ)2 suggests the existence of bigger surface ligands on
the AuNPs (Figure 4A (a, c)). A similar increase in FWHM of the LSPR from Au-GSH-FA to
Au-GSH-FA-(AHQ)2 in 10 mM HEPES pH 6.5 is also observed, confirming the greater HD of
Au-GSH-FA-(AHQ)2 compared to Au-GSH-FA.
No difference in hydrodynamic diameter (HD) of Au-GSH-FA in different buffer
systems, confirming no close interactions between the AuNPs in the absence of the AHQ metal
chelator as observed in UV-Vis (Figure 4B). Nonetheless, in presence of the AHQ chelators, a
significant increase in HD from 44 to 67 nm of Au-GSH-FA-(AHQ)2 at lower pH suggests the
change in the surface ligand structure that lead to the close interactions between the AuNPs. At
pH 8.0, the major GSH-FA-(AHQ)2 species consist of neutral quinoline hydroxyls and amines
that help induce hydrogen bonding between two AHQ residues of one same GSH-FA-(AHQ)2
ligand on the AuNPs.52 Consequently, these hydrogen bonds prevent π-π stacking interactions of
AHQ molecules on different AuNPs from happening. On the contrary, at pH 6.5, the quinoline
amine of one of the AHQ residues of GSH-FA-(AHQ)2 is protonated.52 As a result, it eliminates
hydrogen bonding of two AHQ residues of one same GSH-FA-(AHQ)2 ligand on the AuNPs and
enhances π-π stacking interactions of AHQ molecules on different AuNPs.
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A)

B)
67
44
31 30

Figure 4. (A) Representative LSPR spectra of Au-GSH-FA and Au-GSH-FA-(AHQ)2 in
PBS (a and c) and HEPES (b and d). (B) Average hydrodynamic diameter based on DLS
measurements of Au-GSH-FA and Au-GSH-FA-(AHQ)2 in 10 mM PB pH 8.0 and 10
mM HEPES pH 6.5.

Confirmation of purity and surface modification of AuNPs
The purity of nanoparticles is important for their medicinal applications. Literature
precedents of AuNPs purification include the employment of centrifugation,55 dialysis, and
diafiltration.56 Previously, our group reported the use of ultracentrifugation after every stage of
the synthesis that yields the highest survival rate in zebra fish compared to other purification
techniques.57 Using PES membrane concentrators with a specified molecular weight cut-off, this
method has been shown to be efficient in reducing purification time and solvent waste, yet able
to separate biomolecules from nanomaterials and provide AuNPs with high biocompatibility and
stability.57–60 In this work, ultracentrifugation is employed to purify the two types of AuNPs.
Purity of the AuNPs is important towards determining the conjugation of thiolated ligands on
AuNPs surface as well as evaluating the metal affinity of the designed AuNP since the presence
of excess ligands could limit the capacity of AuNPs to bind to metal ions.
To access the purity of the AuNPs after ultracentrifugation, TLC, UV-Vis, and
fluorescence are employed. TLC of the two AuNPs samples is performed using a mixture of
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butanol/acetic acid/H2O (12:3:5) followed by spraying with ninhydrin. Pictures of TLC plates of
unpurified and purified of Au-GSH-FA (Figure 5A) and Au-GSH-FA-(AHQ)2 (Figure 5B) and
their precursor thiolated ligands are shown in Figure 5. No spot is observed on the lanes of
unpurified and purified Au-GSH-FA (Figure 5A (i-a, c)) upon spraying with ninhydrin
compared to that of free GSH-FA (Figure 5A (i-b). This suggests that minimal GSSG exists in
the AuNPs samples or has been removed by ultracentrifugation. In addition, fluorescence spots
that are evidence of unpurified Au-GSH-FA under UV-lamp (Figure 5 (ii-a)) are not observed
for purified Au-GSH-FA (Figure 5A (ii-c)), confirming the purity of Au-GSH-FA after
ultracentrifugation. In the case of Au-GSH-FA-(AHQ)2, two spots observed on the lane of GSHFA-(AHQ)2 upon spraying with ninhydrin (Figure 5B (i-b)) are not consistent with that seen
previously (Figure 1C (i)). Nevertheless, TLC of Au-GSH-FA-(AHQ)2 shows no purple spots or
fluorescence traces of the free ligands, confirming the purity of these AuNPs (Figure 5B (i, ii-c)).

A)

i

ii

B)

a b c a b c

i

ii

a b c a b c

Figure 5. Pictures of TLC plates of (a) unpurified AuNPs, (b) precursor thiolated
ligands, (c) purified AuNPs under regular light (i and iii), under UV-lamp (ii and iv),
upon spraying with ninhydrin (iii and iv) and without ninhydrin (i and ii) for (A) AuGSH-FA and (B) Au-GSH-FA-(AHQ)2.

Fluorescence spectroscopy is used to confirm the purity of the AuNPs since FA is a
highly fluorescent molecule (λem = 450 nm upon λex = 350nm). Since AHQ is not fluorescent,
GSH-FA and GSH-FA-(AHQ)2 have similar fluorescence properties as shown in Figure 6A.
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Upon excitation at 350 nm, the purified Au-GSH-FA and Au-GSH-FA-(AHQ)2 exhibit no
emission bands (Figure 6B (a, b) in the region of free ligands. This suggest the absence of free
ligands in the nanoparticle samples and the quenching effect of the gold core as a result of
ligand-gold donor-receptor close distance. Interestingly, the gold core quenches the fluorescence
of the ligands conjugated on its surface, not those of the unconjugated as evidenced by literature
precedence when the fluorescence of excess peptides, tryptophan and dansyl arginine, is
observed in presence of their corresponding peptide-conjugated-glutathione-AuNPs.58 Thus, this
characteristic of AuNPs is useful towards confirming the nanoparticle purity. Though not shown
here, fluorescence as well as UV-Vis of the last permeate of each type of AuNPs after
purification is also taken to further confirm the purity of the AuNPs. No characteristic emission
upon excitation at λex of 350 nm or absorption is observed in the regions of free ligands. Hence,
together with TLC, UV-Vis, and fluorescence spectroscopy verify that ultracentrifugation is an
efficient purification method for derivatized AuNPs and creates a method to access the purity of
functional AuNPs.
In addition to nanoparticle purity, fluorescence spectroscopy is also used to determine the
presence of the thiolated ligands on the AuNPs surface. Fluorescence spectra are taken of the
AuNPs etched with 307 mM potassium cyanide. The latter is a well-known etchant that oxidizes
Au° to AuI and cleaves the ligands from the AuNPs surface in presence of oxygen according to
Elsner’s equation.54,61Although the fluorescence of the ligands is substantially quenched by the
gold core (Figure 6B (a, b)), upon etching, emission bands at 450 nm upon excitation at 350 nm
are observed for both GSH-FA and GSH-FA-(AHQ)2 (Figure 6B (c, d)). This confirms the
conjugation of these thiolates on the AuNP surface. No significant shifts in the emission
wavelengths of the ligands of etched AuNP samples is observed as in the case of tryptophan or
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dansyl arginine,58 suggesting no formation of oxidized species. Nevertheless, due to similar
fluorescence properties of GSH-FA and GSH-FA-( AHQ)2, fluorescence spectroscopy could not

A)

B)

Figure 6. (A) Fluorescence spectra of GSH-FA and GSH-FA-(AHQ)2. (B) Fluorescence
spectra of non-etched (a and b) and etched (c and d) samples of Au-GSH-FA and AuGSH-FA-(AHQ)2 (a and b). λex = 350 nm.
demonstrate the existence of AHQ on the AuNPs.

UV-Vis spectroscopy is used to verify the presence of AHQ on NP surface of 1 mL
samples of purified Au-GSH-FA and Au-GSH-FA-(AHQ)2 of 0.8 O.D. (Figure 7B (a, b)). Upon
etching Au-GSH-FA, a new absorption band appeared at 360 nm indicative of GSH-FA with an
OD of 0.035 (Figure 7B (c)), confirming the presence of this thiolate on the AuNPs surface.
Using the extinction coefficient of FA of 9.12 cm-1mM-1 at 368 nm,49 the number of conjugated
GSH-FA in 1 mL of etched sample of Au-GSH-FA was calculated to be 3.84 nmol after cyanide
etching, providing a coupling efficiency of 67.72%. In the case of Au-GSH-FA-(AHQ)2, upon
etching, two new absorption bands appeared at 260 and 360 nm indicative of GSH-FA-(AHQ)2
(Error! Reference source not found.Error! Reference source not found.B (d)), verifying the
existence of this ligand on the AuNPs. Nevertheless, it is difficult to calculate the coupling
efficiency of Au-GSH-FA-(AHQ)2 since its etched solution contained a mixture of FA and AHQ
with overlapping absorption bands in the region of 200-400 nm. However, 1H NMR confirms the
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presence of the AHQ ligand attached to the precursor and we do not expect it to dissociate from
the GSH-FA framework.
A)

260

B)
270

360

Figure 7. (A) Representative UV-Vis spectra of GSH-FA and GSH-FA-(AHQ)2 in H2O.
(B) UV-Vis spectra of purified samples in H2O of (a) Au-GSH-FA and (b) Au-GSH-FA(AHQ)2 and their etched samples (c and d). Au-GSH-FA: λmax = 521 nm, O.D. = ~0.8.
Au-GSH-FA-(AHQ)2: λmax = 525 nm, O.D. = ~0.8. Etched Au-GSH-FA: λmax = 360 nm,
O.D. = ~0.0355. Etched Au-GSH-FA-(AHQ)2: λmax = 260 nm, O.D. = 0.477; λmax = 360
nm, O.D. = 0.175.
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CHAPTER 5
STUDY ON METAL AFFINITY OF GOLD NANOPARTICLES

To demonstrate that these GSH-modified AuNPs can bind to iron and other metals, we
performed metal binding studies with different types of metal ions at varying concentrations and
under two pH conditions: 10 mM PB at pH 8.0 and 10 mM HEPES at pH 6.5. The AuNP
samples are incubated with metal ions and their UV-Vis and DLS are taken in the absence and
presence of the metal ions.
Representative UV-Vis spectra are shown in Figure 8A, which shows the decrease in
O.D. of Au-GSH-FA-(AHQ)2 in 10 mM HEPES at pH 6.5 in the presence of 33 µM Cu(II),
Fe(II), and Zn(II), suggesting that the metals are binding to the AuNP surface. A similar
observation is observed for this type of AuNP in 10 mM PB at pH 8.0. In the case of the AuGSH-DA derivative, its O.D. increases upon the addition of similar metal ions at pH 8.0 while at
pH 6.5 are observed a decrease for Cu(II) and Fe(III) and a slight increase for Zn(II). The
decrease and increase in O.D. of the AuNPs could be explained by the difference of their
refractive index caused by the presence of different metals that bind to the NP surface ligands
with different affinity and coordination chemistry. For the scope of this study, the change in the
O.D. of the AuNPs is used as a probe to detect the metal binding capacity of the nanoparticles. In
other words, a higher change in O.D. is equivalent to greater binding of the AuNPs to the metal
ions.
In this study, the metal affinity of the AuNPs is accessed through the change in O.D. at
the λmax of the non-metallated AuNPs before and after adding metal ions. Figure 8B illustrates
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the effect of increasing concentrations of metal ions on the O.D. of Au-GSH-FA-(AHQ)2 in 10
mM HEPES pH 6.5. To be specific, the presence of higher concentrations of Cu(II), Fe(III), and
Zn(II) leads to higher change in optical density of the AuNP, thus greater AuNP-metal binding.
However, after 65 µM for Cu(II) and Fe(III) or 98 µM for Zn(II) , no significant change in the
O.D. of the Au-GSH-FA-(AHQ)2 is observed, suggesting the saturation of the metal binding
capacity. Even though not shown here, similar increases in the change of O.D. of the AuNPs in
the presence of varying concentrations of metal ions are also observed for Au-GSH-FA-(AHQ)2
in 10 mM PB pH 8.0, and Au-GSH-FA in both 10 mM HEPES pH 8.0 and 10 mM HEPES pH
6.5. Nonetheless, in these cases, the change of O.D. of the AuNPs does not reach the saturation
point of their metal binding capacity. In other words, at both pH 8.0 and pH 6.5, the Au-GSH-FA
derivative binds efficiently to Cu(II), Fe(III), and Zn(II) with concentrations varying from 33 to
327 µM. In the presence of AHQ, the capacity of the AuNPs to bind to these transition metals is
not limited at pH 8.0, while saturated at 65 µM for Cu(II) and Fe(II), and at 98 µM for Zn(II) at
pH 6.5.
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A)

B)

Figure 8. (A) Representative UV-Vis spectra of Au-GSH-FA-(AHQ)2 in 10 mM HEPES
pH 6.5 without metal and with 33µM Cu(II), Fe(III), and Zn(II). (B) Effect of increasing
concentration of metals on Au-GSH-FA-(AHQ)2 in 10 mM HEPES pH 6.5.

To compare the affinity of each type of AuNPs towards different metals, the AuNPs are
incubated with 33 µM Cu(II), Fe(III), Zn(II), Ca(II), Na(I), and K(I). The percent change in O.D.
of the AuNPs is calculated and are shown in Figure 9. A summary of metal affinity of Au-GSHFA and Au-GSH-FA-(AHQ)2 in different pH environments is found in the table in Figure 9B.
The metal affinity of both Au-GSH-FA and Au-GSH-FA-(AHQ)2 appears to be higher at pH 6.5.
At pH 8.0, Au-GSH-FA binds to Fe(III) less than K(I) > Cu(II) > Na(I), but more than Zn(II) =
Ca(II) while in the presence of the AHQ chelators, the AuNPs appear to bind to Fe(III) less all
than other metals (in increasing order, (K(I) > Cu(II) > Na(I) > Zn(II) > Ca(II)). At pH 6.5,
Fe(III) appears to bind to Au-GSH-FA the most, following by Na(I) > K(I) > Cu(II) > Zn(II) >
Ca(II). However, in presence of the AHQ chelators, this affinity towards Fe(III) is lower than
that of Cu(II) > Zn(II), but higher than that of Ca(II) > K(I) > Na(I).
The difference in metal affinity of the two types of AuNPs could be explained by the
presence of the AHQ chelator. In the case of Cu(II) and Zn(II), Au-GSH-FA-(AHQ)2 appears to
have higher affinity to these metals than Au-GSH-FA at pH 6.5. This could be explained by the
1,4-position of the O and N donors of the AHQ quinolines that form better coordination
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geometry towards Cu(II) and Zn(II). In the case of Fe(III), Au-GSH-FA appears to have higher
affinity to this metal ion than Au-GSH-FA-(AHQ)2 at pH 6.5. The GSH-FA ligands have three
carboxylate residues (two of the GSH and one of the FA) available for coordination chemistry,
which would easily form complexes with Fe(III), hence, Au-GSH-FA binds to Fe(III) more
efficiently than Au-GSH-FA-(AHQ)2.
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Cancer cells are known to have acidic extracellular environment with pH values ranging
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from 5.9 to 7.6.62 Considering the effect of pH on metal affinity of AuNPs, UV-Vis data suggest
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that Au-GSH-FA-(AHQ)2 binds to Ca(II), Na(II), and K(I) less than Au-GSH-FA in both basic
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and acidic environments (Figure 9). Nevertheless, Au-GSH-FA tends to bind to these trace
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metals more at lower pH (Figure 9) while Au-GSH-FA-(AHQ)2 binds substantially less to Na(I)
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and K(I) and only slightly more to Ca(II). Regarding Cu(II), Fe(III), and Zn(II), both types of
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AuNPs, especially Au-GSH-FA-(AHQ)2, appear to bind to these metals more in acidic
environment. At pH 6.5, Au-GSH-FA appears to have much lower affinity to Cu(II) and Zn(II)
than to Fe(III). Especially, in acidic media, these AuNPs bind to Fe(III) substantially more than
Ca(II), Na(I), and K(I). Au-GSH-FA-(AHQ)2, in contrast, are shown to have much higher
affinity to Cu(II) and Zn(II) than Fe(III). Given these trends, Au-GSH-FA could be employed as
a nanochelator for Fe(III) while Au-GSH-FA-(AHQ)2 is ideal for for Cu(II) and Zn(II) metal ion
capture. Nonetheless, since the affinity of Au-GSH-FA-(AHQ)2 toward Fe(III) is still higher
than toward Ca(II), Na(I), and K(I), the use of this type of AuNP as a nanochelator for Fe(III) is
still applicable. Despite the purpose of this study in synthesizing gold nanochelators for iron,
these results opens door for the use of both types of AuNPs as nanochelators for different cancers
where Cu(II), Fe(III), and Zn(II) exist at different levels and play different roles in tumor

A)

ii

i

Au-GSH-FA

10 mM PB pH 8.0
K(I) > Cu(II) > Na(I) > Fe(III) > Zn(II) = Ca(II)

Au-GSH-FA-(AHQ)2

K(I) > Cu(II) > Na(I) > Zn(II) > Ca(II) > Fe(III)

B)

10 mM HEPES pH 6.5
Au-GSH-FA

Fe(III) > Na(I) > K(I) > Cu(II) > Zn(II) > Ca(II)

Au-GSH-FA-(AHQ)2

Cu(II) > Zn(II) > Fe(III) > Ca(II) > K(I) > Na(I)

Figure 9. (A) Percent change in O.D. of (i) Au-GSH-FA and (ii) Au-GSH-FA-(AHQ)2 in
10 mM PB pH 8.0 and 10 mM HEPES pH 6.5. (B) Summary of metal affinity based on
UV-Vis of Au-GSH-FA and Au-GSH-FA-(AHQ)2 in 10 mM PB pH 8.0 and 10 mM
HEPES pH 6.5.
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development (Table 3).63,64
The capacity of the AuNPs to bind to metal ions could also be determined by the change
in their HD in the presence of the metal ions using DLS. In presence of metal ions, the AuNPs
are hypothesized to form nanoparticle-nanoparticle interactions through metal-surface ligand
bindings (Figure 10A). The difference between DLS and UV-Vis in terms of metal binding of
AuNPs is that DLS determines the HD of the AuNP-metal clusters. For instance, in 10 mM
HEPES at pH 6.5, the Au-GSH-FA-derivative forms bigger clusters with 33 µM Cu(II) than with
Zn(II) > Fe(III) at the same concentration (Figure 10B). In this manner, a summary of the HDs
of the AuNP-metal clusters formed by Au-GSH-FA and Au-GSH-FA-(AHQ)2 upon the addition
of 33 µM Cu(II), Fe(III), and Zn(II) at pH 8.0 and pH 6.5 could be found in Figure 11C.

A)

B)

Figure 10. (A) Effect of metal ions on hydrodynamic diameter of AuNPs. (B)
Representative DLS data of Au-GSH-FA-(AHQ)2 in presence of Cu(II), Fe(III), and
Zn(II) in 10 mM HEPES pH 6.5.

Both types of AuNPs do not form big clusters with the three selected transition metals at
pH 8.0 compared to at pH 6.5, confirming the trend observed with UV-Vis data that the AuNPs
bind better to the metals at lower pH. At pH 8.0, the clusters formed by Au-GSH-FA with Cu(II),
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Fe(III), and Zn(II) are almost of the same size as in the absence of these metals (34, 30, 30 vs. 31
nm). In contrast, a significant increase in HD of the [Au-GSH-FA]-metal clusters is observed at
pH 6.5, following the increasing order: Cu(II) (402 nm) > Fe(III) (131 nm) > Zn(II) (48 nm). In
presence of the AHQ chelator, at pH 8.0, the AuNPs form bigger clusters with Cu(II) (67 nm)
than with Zn(II) (55 nm) > Fe(III) (48 nm), compared to in the absence of these metals (44 nm).
Similar to Au-GSH-FA, a significant increase in HD of the nanoparticle-metal clusters formed

B)

C)

i

ii

10 mM PB pH 8.0
Au-GSH-FA

Cu(II) > Fe(III) = Zn(II)

Au-GSH-FA-(AHQ)2

Cu(II) > Zn(II) > Fe(III)
10 mM HEPES pH 6.5

Au-GSH-FA

Cu(II) > Fe(III) > Zn(II)

Au-GSH-FA-(AHQ)2

Cu(II) > Zn(II) > Fe(III)

Figure 11. (A) Hydrodynamic diameter (nm) of (i) Au-GSH-FA and (ii) Au-GSH-FA(AHQ)2 in 10 mM PB pH 8.0 and 10 mM HEPES pH 6.5. (C) Summary of HDs of
AuNP-metal clusters ofAu-GSH-FA and Au-GSH-FA-(AHQ)2 in 10 mM PB pH 8.0 and
10 mM pH 6.5.
by this type of AuNP is observed at pH 6.5, following the increasing order: Cu(II) (3905 nm) >
Zn(II) (2976 nm) > Fe(III) (830 nm) in comparison with in the absence of the metals (67 nm).
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Table 3. Concentration (µg/g tissue) of Cu(II), Fe(III), and Zn(II) in certain cancerous
tissues.61
Tissue
Breast
Thyroid
Kidney
Stomach
Penis
Testis

Cu(II)
Normal
Cancerous
42
60.7
54.9
12.9
9.1
8.2
63.5
21.2
7.5
79.6
3.9
14.9

Fe(III)
Normal
Cancerous
299
376
569
1397
325
305
2408
684
650
464
426.4
391.9
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Zn(II)
Normal
Cancerous
56
126
149
71.8
66
78
818
229
58.2
148
91.7
34
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CHAPTER 6

CONCLUDING REMARKS

In summary, a new class of water-soluble peptide-capped highly-purified AuNPs
carrying both cancer targeting moieties and iron chelators for the use in cancer therapy is
developed. The FA cancer targeting moieties and AHQ iron chelators are conjugated on
glutathione synthons using DIC/NHS coupling chemistry. The GSH-FA and GSH-FA-(AHQ)2
were conjugated onto the AuNPs surface through their thiol function groups, followed by
extensive ultracentrifugation to remove possible excess precursors. The conjugation of the AHQ
and FA molecules to GSH were confirmed by TLC, UV-Vis, and 1H NMR spectroscopies. The
two AuNPs species were denoted Au-GSH-FA and Au-GSH-FA-(AHQ)2.
TLC, UV-Vis, and fluorescence spectroscopic techniques verified the AuNPS purity after
their synthesis. In addition, UV-Vis and fluorescence were also employed to determine the
presence of the thiolates on the AuNPs surface. Based on calculation using UV-Vis data, AuGSH-FA had a coupling efficiency of 67.72%. It was, in contrast, difficult to determine the
ligand coverage percentage on Au-GSH-FA-(AHQ)2.
Metal binding study was performed to determine the ability of Au-GSH-FA and AuGSH-FA-(AHQ)2 to bind to metals using UV-Vis and DLS. It was found that in acidic
environments such as that in tumors, Au-GSH-FA-(AHQ)2 bind considerably efficiently to
Cu(II) > Zn(II) > Fe(III), but very minimally to Ca(II) > K(I) > Na(I) while Au-GSH-FA bind
substantially to Fe(III) compared to other metal ions. These trends opened door for the use of
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both types of AuNPs as nanochelators towards Cu(II), Fe(III), and Zn(II) in different cancerous
tissues where Cu(II) and Zn(II) are also shown to play more important roles than Fe(III).
Regarding copper, this transition metal is an important cofactor for angiogenesis, a
crucial process for tumor development.65 It has been proved that there is a correlation between
high concentrations of copper and cancer progression through the formation of reactive oxidative
species (ROS),66 such as such as O2− and OH radicals, as a result of Cu-DNA affinity and Fenton
reactions in the presence of peroxide.67 In the case of zinc, as this metal is not redox-active, it is
thus not involved in the production of ROS species. On the one hand, at low levels, zinc
inactivates p53, a tumor suppressor protein, leading to carcinogenesis in thyroid. On the other
hand, at high levels, this transition metal is proved to promote tumor growth by enhancing
telomerase enzyme, a transferase responsible for extending DNA strands at the 3’ end in the
tolemere regions, and reducing the inhibitory effect of bisphosphonates on tumor cell invasion as
well as the development of neoplastic transformation in penis cancer.64,68 Thus, with the high
affinity of the nanochelators Au-GSH-FA-(AHQ)2 towards Cu(II) and Zn(II) in acidic
environment, this type of AuNPs are suitable for chelating these transition metals.
In conclusion, the study reported the synthesis of a new class of AuNPs to chelate not
only iron, but also copper and zinc for cancer therapy. This method is unique since it allows for
creating a novel class of highly biocompatible and flexibly tailored AuNPs system to remove
metals. This design concept is thus not limited to just cancer, but could expand its scope to other
metal-associated diseases like Alzheimer's and Parkinson's diseases.
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